+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
NGS-Based RNA-Sequencing Market - Global Forecast 2026-2032- Product Image
NGS-Based RNA-Sequencing Market - Global Forecast 2026-2032- Product Image
Sale

NGS-Based RNA-Sequencing Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5533389
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The NGS-Based RNA-Sequencing Market is projected to reach USD 3.77 Billion in 2026. It is expected to continue growing at a CAGR of 19.74%, reaching USD 11.20 Billion by 2032.

NGS-based RNA sequencing, often searched as RNA-seq or next-generation RNA sequencing, enables transcriptome profiling by converting RNA into sequencing-ready libraries and aligning reads to reveal gene expression, isoforms, fusions, splice variants, allele-specific expression, and noncoding RNA activity. The technology is central to precision oncology, immunology, infectious disease research, single-cell biology, neuroscience, rare disease investigation, and biomarker discovery.

Adoption is supported by the well-documented decline in sequencing costs, improved library preparation, higher-throughput instruments, cloud bioinformatics, and expanding clinical evidence for transcriptomic biomarkers. Industry demand is strongest where organizations need high-resolution, hypothesis-free analysis that goes beyond targeted assays and supports reproducible discovery across research, translational, and diagnostic workflows.

Transformative Shifts in the RNA-Seq Landscape

The RNA sequencing landscape is shifting from bulk transcriptomics toward single-cell RNA-seq, spatial transcriptomics, long-read RNA sequencing, and multiomics workflows. These approaches help researchers connect gene expression with cell identity, tissue architecture, epigenetic regulation, immune status, and proteomic signals, improving biological interpretation in cancer, neuroscience, immunology, developmental biology, and rare disease studies.

Clinical translation is also accelerating as standardized sample handling, automation, quality-control metrics, external proficiency testing, and validated bioinformatics pipelines reduce variability. At the same time, demand for decentralized sequencing, companion diagnostic development, liquid biopsy research, pathogen transcriptomics, and population-scale transcriptome analysis is reshaping procurement decisions across academic centers, hospitals, contract research organizations, public health laboratories, and biopharma research teams.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical layer across NGS-based RNA sequencing, especially for read quality control, transcript quantification, splice-event detection, variant interpretation, cell-type annotation, pathway analysis, phenotype prediction, and clinical report drafting. Machine learning models are improving signal detection in noisy datasets and helping prioritize biomarkers from high-dimensional transcriptomic data generated through bulk, single-cell, and spatial sequencing workflows.

The cumulative impact is higher analytical throughput, faster decision-making, and improved consistency in complex transcriptome interpretation, but governance remains essential. Leaders must manage model bias, training-data transparency, explainability, cybersecurity, privacy protection, and regulatory expectations for software used in clinical or research decision support. AI-enabled RNA-seq delivers the most value when paired with curated reference datasets, auditable workflows, human expert review, and validated molecular interpretation standards.

Key Regional Insights

North America remains a leading region for NGS-based RNA sequencing due to strong publicly funded genomics research, advanced cancer centers, established molecular pathology networks, mature biopharma research activity, and a dense ecosystem of sequencing infrastructure, cloud computing, and bioinformatics expertise. The United States anchors demand through precision oncology, rare disease research, immunotherapy development, and public health genomics, while Canada contributes through population genomics, academic research networks, cancer programs, and precision medicine initiatives.

Europe benefits from cross-border research programs, national genomics strategies, biobank infrastructure, cancer research networks, and a strong regulatory emphasis on data protection, clinical evidence, and laboratory quality systems. Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, Singapore, and Australia invest in genomics infrastructure, oncology research, infectious disease surveillance, single-cell platforms, and translational medicine. Latin America is strengthening RNA-seq adoption through academic collaborations, oncology studies, infectious disease research, and agricultural biotechnology, with Brazil and Mexico acting as important regional contributors. The Middle East is advancing through national genome programs, precision medicine investments, and modern tertiary hospital networks, especially in Gulf economies. Africa is earlier in adoption but shows rising demand through pathogen surveillance, population genetics, capacity-building programs, cancer research partnerships, and regional laboratory modernization.

Key Group Insights

Within ASEAN, Singapore acts as a regional genomics and biomedical research hub supported by advanced clinical research infrastructure, strong data capabilities, and public-sector investment, while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are expanding sequencing access through universities, reference laboratories, cancer centers, and public health programs. The GCC is investing in precision medicine, national genome initiatives, newborn and rare disease research, and advanced hospital networks, creating demand for clinical-grade RNA-seq infrastructure, secure bioinformatics, and locally compliant data governance.

The European Union supports RNA sequencing through collaborative research funding, cancer mission programs, rare disease networks, biobanks, and harmonized data-governance frameworks that influence clinical-grade transcriptomics adoption. BRICS markets combine large patient populations, expanding local sequencing capacity, and growing pharmaceutical and academic research activity, although reimbursement, procurement maturity, and data-infrastructure readiness vary by country. G7 countries lead in research intensity, diagnostics adoption, regulatory development, and bioinformatics depth, while NATO member states increasingly view genomics, pathogen surveillance, resilient supply chains, and secure health-data infrastructure as strategic capabilities for public health and biosecurity.

Key Country Insights

The United States leads global commercialization of NGS-based RNA sequencing through academic medical centers, biopharma R&D, precision oncology programs, rare disease research, public health sequencing networks, and sequencing technology innovation. Canada emphasizes research networks, population genomics, cancer research, and equitable access, while Mexico and Brazil are expanding RNA-seq through oncology, infectious disease, microbiology, and agricultural biotechnology research. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong life sciences ecosystems with national genomics, cancer research, biobank programs, and molecular pathology capabilities, while Russia maintains selective genomics capabilities in academic, clinical, and state-backed research institutions.

China has scaled sequencing capacity through hospital networks, domestic genomics infrastructure, government-supported precision medicine programs, oncology research, and population-scale initiatives. India is building momentum through cost-efficient sequencing services, population diversity studies, infectious disease research, cancer genomics, and expanding bioinformatics talent. Japan, South Korea, and Australia show strong demand for clinical research, single-cell RNA sequencing, immunology, neuroscience, oncology, and translational medicine, supported by advanced healthcare systems, biomedical funding, and established academic-industry collaboration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated workflows rather than competing only on sequencing throughput. High-value opportunities include single-cell RNA-seq, spatial transcriptomics, FFPE-compatible assays, liquid biopsy research, long-read transcriptomics, pathogen transcriptomics, immune repertoire analysis, and integrated DNA-RNA panels for oncology, rare disease, and fusion detection applications.

Organizations should invest in automation, sample-quality controls, validated pipelines, secure cloud infrastructure, interoperability, and data standards that support reproducibility across laboratories. Commercial teams should align offerings with clinical evidence, regulatory readiness, reimbursement strategy, laboratory accreditation requirements, and regional data-sovereignty rules. Partnerships with hospitals, contract research organizations, biobanks, public health laboratories, and AI developers can accelerate adoption while reducing operational friction and strengthening trust in RNA-seq results.

Research Methodology

This executive summary is based on secondary research from publicly available and reputable sources, including government genomics programs, peer-reviewed literature, regulatory agency guidance, public health organizations, clinical genomics initiatives, standards bodies, and published biomedical research. The analysis emphasizes verified technology, regulatory, and adoption trends rather than speculative market sizing, market share, or forecasting.

Research inputs were synthesized across technology adoption, regional investment, clinical translation, regulatory maturity, data-governance requirements, end-user demand, and application relevance. The methodology prioritizes triangulation across independent sources, consistency checks, terminology normalization, and relevance to NGS-based RNA sequencing applications in research, diagnostics, pharmaceutical development, precision medicine, and public health surveillance.

Conclusion

NGS-based RNA sequencing is moving from specialized research use toward a broader role in precision medicine, translational research, public health genomics, and data-driven drug development. Its ability to measure transcript-level biology at scale makes it essential for biomarker discovery, immune profiling, tumor characterization, fusion detection, drug response studies, and complex disease research.

The next phase of competition will be defined by workflow reliability, AI-enabled interpretation, regional access, regulatory confidence, data security, and integration with multiomics platforms. Organizations that combine scientific rigor with scalable informatics, validated quality systems, and clinical-grade execution will be best positioned to lead in NGS-based RNA sequencing.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. NGS-Based RNA-Sequencing Market, by Product
7.1. Introduction
7.2. Consumables
7.2.1. Enzymes
7.2.2. Reagents And Kits
7.3. Instruments
7.3.1. Data Analysis Platforms
7.3.2. Library Prep Instruments
7.3.3. Sequencers
7.4. Services
7.4.1. Bioinformatics Analysis Services
7.4.2. Project Management Services
7.4.3. Sample Preparation Services
8. NGS-Based RNA-Sequencing Market, by Technology
8.1. Introduction
8.2. Bulk Sequencing
8.3. Long-Read Sequencing
8.4. Single-Cell Sequencing
8.5. Spatial Transcriptomics
9. NGS-Based RNA-Sequencing Market, by Application
9.1. Introduction
9.2. Biomarker Discovery
9.2.1. Early-Stage Biomarker Identification
9.2.2. Validation
9.3. Drug Discovery & Development
9.3.1. Pharmacokinetic Studies
9.3.2. Target Identification
9.3.3. Toxicology Studies
9.4. Gene Expression Profiling
9.4.1. Bulk Profiling
9.4.2. Single-Cell Profiling
9.4.3. Spatial Profiling
9.5. Personalized Medicine
9.5.1. Companion Diagnostics
9.5.2. Therapeutic Monitoring
10. NGS-Based RNA-Sequencing Market, by End User
10.1. Introduction
10.2. Academic & Government
10.2.1. Research Institutes
10.2.2. Universities
10.3. Clinical Diagnostics Laboratories
10.3.1. Hospital Laboratories
10.3.2. Independent Laboratories
10.4. Contract Research Organizations
10.5. Pharmaceutical & Biotechnology Companies
10.5.1. Biotechnology Companies
10.5.2. Pharmaceutical Companies
11. NGS-Based RNA-Sequencing Market, by Distribution Channel
11.1. Introduction
11.2. Online
11.3. Offline
12. NGS-Based RNA-Sequencing Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. NGS-Based RNA-Sequencing Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. NGS-Based RNA-Sequencing Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. 10x Genomics Inc
16.2. Agilent Technologies Inc
16.3. Becton Dickinson and Company
16.4. BGI Group
16.5. Danaher Corporation
16.6. Eurofins Scientific SE
16.7. F Hoffmann-La Roche Ltd
16.8. Fulgent Genetics Inc
16.9. GenScript Biotech Corporation
16.10. Hamilton Company
16.11. Illumina Inc
16.12. LGC Limited
16.13. MGI Tech Co Ltd
16.14. NeoGenomics Laboratories Inc
16.15. New England Biolabs Inc
16.16. Novogene Co Ltd
16.17. Oxford Nanopore Technologies PLC
16.18. Pacific Biosciences of California Inc
16.19. Promega Corporation
16.20. Psomagen Inc
16.21. QIAGEN N V
16.22. Revvity Inc
16.23. SD Biosensor Inc
16.24. Takara Bio Inc
16.25. Tecan Trading AG
16.26. Thermo Fisher Scientific Inc
16.27. Twist Bioscience Corporation
16.28. WuXi Biologics Cayman Inc
List of Figures
FIGURE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL REAGENTS AND KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL REAGENTS AND KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL REAGENTS AND KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL LIBRARY PREP INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LIBRARY PREP INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LIBRARY PREP INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SEQUENCERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SEQUENCERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SEQUENCERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BIOINFORMATICS ANALYSIS SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BIOINFORMATICS ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BIOINFORMATICS ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PROJECT MANAGEMENT SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PROJECT MANAGEMENT SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PROJECT MANAGEMENT SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SAMPLE PREPARATION SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SAMPLE PREPARATION SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL SAMPLE PREPARATION SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BULK SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BULK SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BULK SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL LONG-READ SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL LONG-READ SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL LONG-READ SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SINGLE-CELL SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SINGLE-CELL SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SINGLE-CELL SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SPATIAL TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SPATIAL TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SPATIAL TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL EARLY-STAGE BIOMARKER IDENTIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL EARLY-STAGE BIOMARKER IDENTIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL EARLY-STAGE BIOMARKER IDENTIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL VALIDATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL VALIDATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL VALIDATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PHARMACOKINETIC STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PHARMACOKINETIC STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PHARMACOKINETIC STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL GENE EXPRESSION PROFILING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL GENE EXPRESSION PROFILING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL GENE EXPRESSION PROFILING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL BULK PROFILING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL BULK PROFILING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL BULK PROFILING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SINGLE-CELL PROFILING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SINGLE-CELL PROFILING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SINGLE-CELL PROFILING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SPATIAL PROFILING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SPATIAL PROFILING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL SPATIAL PROFILING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ACADEMIC & GOVERNMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ACADEMIC & GOVERNMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ACADEMIC & GOVERNMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL UNIVERSITIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL UNIVERSITIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL UNIVERSITIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL CLINICAL DIAGNOSTICS LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL CLINICAL DIAGNOSTICS LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL CLINICAL DIAGNOSTICS LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 181. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 182. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 183. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 184. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 185. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 186. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 188. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 189. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 190. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 191. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 192. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 193. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 194. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 195. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 213. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 214. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 215. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 216. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 217. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 218. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 219. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 220. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 221. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 222. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 223. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 225. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 226. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 227. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 230. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 231. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 232. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 233. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 234. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 235. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 236. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 237. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 238. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 239. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 240. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 242. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 243. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 244. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 246. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 247. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 248. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 249. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 250. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 251. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 252. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 253. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 254. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 255. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 256. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 258. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 259. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 260. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 278. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 279. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 280. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 281. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 282. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 283. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 284. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 285. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 286. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 287. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 288. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 290. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 291. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 292. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 293. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 294. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 295. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 296. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 297. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 298. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 299. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 300. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 301. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 302. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 303. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 304. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 305. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 306. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 307. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 308. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 310. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 311. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 312. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 313. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 314. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 315. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 316. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 317. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 318. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 319. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 320. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2017-2032 (USD MILLION)
TABLE 322. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2017-2032 (USD MILLION)
TABLE 323. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 324. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 325. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 328. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 331. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 332. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 333. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2017-2032 (USD MILLION)
TABLE 334. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 335. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2017-2032 (USD MILLION)
TABLE 336. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2017-2032 (USD MILLION)
TABLE 337. UNITED STATES NGS-BASED RNA-SEQUENCING

Companies Mentioned

  • 10x Genomics Inc
  • Agilent Technologies Inc
  • Becton Dickinson and Company
  • BGI Group
  • Danaher Corporation
  • Eurofins Scientific SE
  • F Hoffmann-La Roche Ltd
  • Fulgent Genetics Inc
  • GenScript Biotech Corporation
  • Hamilton Company
  • Illumina Inc
  • LGC Limited
  • MGI Tech Co Ltd
  • NeoGenomics Laboratories Inc
  • New England Biolabs Inc
  • Novogene Co Ltd
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California Inc
  • Promega Corporation
  • Psomagen Inc
  • QIAGEN N V
  • Revvity Inc
  • SD Biosensor Inc
  • Takara Bio Inc
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc
  • Twist Bioscience Corporation
  • WuXi Biologics Cayman Inc

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.77 Billion
Forecasted Market Value ( USD ) by 2032 $ 11.2 Billion
Compound Annual Growth Rate19.7%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

NGS Sample Preparation Market - Global Forecast 2026-2032 - Product Image

NGS Sample Preparation Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
NGS Library Preparation Automation Market - Global Forecast 2026-2032 - Product Image

NGS Library Preparation Automation Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
NGS-Based RNA-Sequencing - Global Strategic Business Report - Product Image

NGS-Based RNA-Sequencing - Global Strategic Business Report

  • Report
  • 220 Pages
  • Global
From
Ngs-Based Rna-Sequencing Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Ngs-Based Rna-Sequencing Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
MicroRNA Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

MicroRNA Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 280 Pages
  • Global
From

About the Next Generation RNA Sequencing Market

The Next Generation RNA Sequencing (NGS) market is a rapidly growing segment of the genomics industry. NGS is a powerful tool for studying gene expression, which is the process by which genetic information is used to produce proteins and other molecules. NGS enables researchers to analyze the expression of thousands of genes simultaneously, providing a comprehensive view of gene expression in a single experiment. This technology has been used to study a wide range of biological processes, including cancer, neurological disorders, and infectious diseases. NGS has also been used to identify novel biomarkers and therapeutic targets, as well as to develop personalized medicine. In addition, NGS has enabled researchers to study the evolution of genes and to identify genetic variants associated with disease. Companies in the Next Generation RNA Sequencing market include Illumina, Thermo Fisher Scientific, BGI, Oxford Nanopore Technologies, Pacific Biosciences, and 10X Genomics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.